NEW YORK (GenomeWeb News) – Affymetrix said today that Medical Prognosis Institute, a cancer diagnostic firm based in Denmark, will use the Affy microarray platform to develop drug sensitivity prediction and prognostic tools for patients with cancer.
Under the terms of the “Powered by Affymetrix” agreement, MPI gains non-exclusive access to Affy’s technology to develop and commercialize tools that will identify patients likely to respond to anti-cancer drugs.
The partnership “also boosts the probability of successful anti-cancer drug development in partnership with drug companies," Jesper Drejet, president and CEO of MPI, said in a statement.
Drejet added that the company is “confident” that it will be able to obtain regulatory clearance and begin commercializing its tests within one to two years.
Affymetrix and its PbA partners are currently developing more than 20 different tests on the Affy microarray platform, the company said.